Sihuan Pharmaceutical Holdings Group Future Growth
Future criteria checks 5/6
Sihuan Pharmaceutical Holdings Group is forecast to grow earnings and revenue by 95.1% and 26.9% per annum respectively. EPS is expected to grow by 99.8% per annum. Return on equity is forecast to be 12.3% in 3 years.
Key information
95.1%
Earnings growth rate
99.76%
EPS growth rate
| Pharmaceuticals earnings growth | 13.9% |
| Revenue growth rate | 26.9% |
| Future return on equity | 12.33% |
| Analyst coverage | Low |
| Last updated | 09 Sep 2025 |
Recent future growth updates
Recent updates
Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) P/S Is On The Mark
Oct 15
Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) Shares Climb 28% But Its Business Is Yet to Catch Up
Jun 24What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 29% Share Price Gain Is Not Telling You
May 07Pinning Down Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) P/S Is Difficult Right Now
Feb 21What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You
Oct 02Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?
Sep 30Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year
May 31Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
May 27A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Dec 05Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?
Oct 31Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Aug 19Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Apr 21Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?
Nov 03Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Oct 11Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?
Jun 21Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Mar 09A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Nov 28Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly
Sep 26We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now
Jun 22How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?
May 11Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit
Mar 30How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?
Mar 07Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?
Feb 07
Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)
Jan 11Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?
Dec 21Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters
Dec 07Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2027 | 4,104 | 797 | 836 | 1,110 | 1 |
| 12/31/2026 | 3,229 | 449 | 423 | 726 | 1 |
| 12/31/2025 | 2,463 | 127 | -97 | 338 | 1 |
| 6/30/2025 | 2,098 | -81 | -65 | 112 | N/A |
| 3/31/2025 | 1,999 | -149 | 0 | 178 | N/A |
| 12/31/2024 | 1,901 | -217 | 64 | 244 | N/A |
| 9/30/2024 | 1,828 | -127 | 12 | 226 | N/A |
| 6/30/2024 | 1,755 | -38 | -40 | 208 | N/A |
| 3/31/2024 | 1,808 | -46 | -68 | 204 | N/A |
| 12/31/2023 | 1,861 | -54 | -96 | 199 | N/A |
| 6/30/2023 | 1,773 | -2,041 | -697 | -300 | N/A |
| 3/31/2023 | 1,977 | -1,996 | -620 | -127 | N/A |
| 12/31/2022 | 2,181 | -1,951 | -543 | 46 | N/A |
| 6/30/2022 | 2,595 | -144 | -306 | 425 | N/A |
| 3/31/2022 | 2,817 | 141 | -183 | 545 | N/A |
| 12/31/2021 | 3,038 | 427 | -60 | 665 | N/A |
| 9/30/2021 | 3,304 | 681 | 63 | 740 | N/A |
| 6/30/2021 | 3,317 | 945 | 187 | 815 | N/A |
| 3/31/2021 | 2,891 | 727 | -83 | 521 | N/A |
| 12/31/2020 | 2,464 | 508 | -353 | 227 | N/A |
| 9/30/2020 | 2,370 | -14 | -429 | 214 | N/A |
| 6/30/2020 | 2,275 | -537 | -504 | 200 | N/A |
| 3/31/2020 | 2,577 | -1,623 | 162 | 809 | N/A |
| 12/31/2019 | 2,878 | -2,709 | 828 | 1,418 | N/A |
| 9/30/2019 | 3,088 | -1,927 | 1,238 | 1,726 | N/A |
| 6/30/2019 | 3,297 | -1,144 | 1,647 | 2,033 | N/A |
| 3/31/2019 | 3,107 | 238 | N/A | 1,913 | N/A |
| 12/31/2018 | 2,917 | 1,620 | N/A | 1,793 | N/A |
| 9/30/2018 | 2,751 | 1,496 | N/A | 1,906 | N/A |
| 6/30/2018 | 2,584 | 1,372 | N/A | 2,019 | N/A |
| 3/31/2018 | 2,665 | 1,411 | N/A | 1,968 | N/A |
| 12/31/2017 | 2,746 | 1,449 | N/A | 1,918 | N/A |
| 9/30/2017 | 2,992 | 1,632 | N/A | 1,889 | N/A |
| 6/30/2017 | 3,238 | 1,815 | N/A | 1,860 | N/A |
| 3/31/2017 | 3,212 | 1,761 | N/A | 1,939 | N/A |
| 12/31/2016 | 3,186 | 1,708 | N/A | 2,018 | N/A |
| 9/30/2016 | 2,984 | 1,528 | N/A | 2,037 | N/A |
| 6/30/2016 | 2,781 | 1,347 | N/A | 2,056 | N/A |
| 3/31/2016 | 2,974 | 1,705 | N/A | 1,812 | N/A |
| 12/31/2015 | 3,167 | 2,062 | N/A | 1,569 | N/A |
| 9/30/2015 | 3,321 | 2,181 | N/A | 1,691 | N/A |
| 6/30/2015 | 3,474 | 2,299 | N/A | 1,813 | N/A |
| 3/31/2015 | 3,279 | 1,985 | N/A | 1,787 | N/A |
| 12/31/2014 | 3,084 | 1,671 | N/A | 1,761 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 460 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.7%).
Earnings vs Market: 460 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 460 is expected to become profitable in the next 3 years.
Revenue vs Market: 460's revenue (26.9% per year) is forecast to grow faster than the Hong Kong market (8.6% per year).
High Growth Revenue: 460's revenue (26.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 460's Return on Equity is forecast to be low in 3 years time (12.3%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/20 19:18 |
| End of Day Share Price | 2025/10/20 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Sihuan Pharmaceutical Holdings Group Ltd. is covered by 21 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shaojing Tong | BofA Global Research |
| Harry He | China Galaxy International Securities (Hong Kong) |
| Xiaofang Xu | Citic Securities Co., Ltd. |